Literature DB >> 8226145

Inoperable endobronchial obstructing lung cancer treated with combined endobronchial and external beam irradiation: a dosimetric analysis.

G W Cotter1, C Lariscy, K E Ellingwood, D Herbert.   

Abstract

PURPOSE: This study is a dosimetric review of our experience incorporating both external beam radiotherapy and endobronchial brachytherapy in the treatment of inoperable endobronchial obstructing lung cancer. METHODS AND MATERIALS: Sixty-five patients with symptomatic inoperable endobronchial obstructing lung cancer received combined external beam radiotherapy and temporary endobronchial iridium (Ir)-192 implants between February 1987 and May 1991. External beam irradiation doses ranged from 55 to 66 Gy. Patients were given 2 to 4 temporary Ir-192 endobronchial implants at the site of endobronchial obstruction. Individual implant doses ranged from 2.7 to 10 Gy. Total implant doses ranged from 6 to 35 Gy. Total treatment doses ranged from 61 to 96.6 Gy.
RESULTS: Sixty-three percent of patients had a complete local endobronchial response to treatment and 23% had a partial response. Forty-seven percent of patients receiving a total dose of less than 70 Gy experienced a complete local endobronchial response to treatment while 83% of patients receiving a total dose of 85 Gy or greater experienced a complete local endobronchial response to treatment. Sixty-six percent experienced an improvement in their performance status using an Eastern Cooperative Oncology Group performance scale. Survival from the end of treatment was 38% at 1 year and 23% at 2 years, with the median survival at 8 months. Complications occurred in 9/65 (14%) of patients; 0% in patients receiving a total dose of less than 70 Gy, 10% in patients receiving a total dose of 70 to 84.99 Gy, and 24% of patients receiving a total dose of 85 Gy or higher.
CONCLUSION: The data from this study again confirms the feasibility of this form of treatment for inoperable endobronchial obstructing lung cancer. In addition, there appears to be a dose response for both local response and complications.

Entities:  

Mesh:

Year:  1993        PMID: 8226145     DOI: 10.1016/0360-3016(93)90376-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

Review 1.  HDR endobronchial brachytherapy in palliative and combined radical treatment of lung cancer.

Authors:  Jacek Fijuth
Journal:  J Contemp Brachytherapy       Date:  2010-01-13

Review 2.  Brachytherapy in the treatment of lung cancer - a valuable solution.

Authors:  Janusz Skowronek
Journal:  J Contemp Brachytherapy       Date:  2015-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.